Pinnacle Wealth Planning Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$152K	Sell	7,530 -2,973	-28%	-$79.8K	0.01%	626
2026 Q2	$266K	Sell	10,503 -96	-0.9%	-$2.11K	0.03%	420
2026 Q1	$236K	Sell	10,599 -594	-5%	-$14.2K	0.02%	421
2025 Q4	$299K	Sell	11,193 -282	-2%	-$6.74K	0.03%	327
2025 Q3	$245K	Buy	11,475 +1	+0%	+$24	0.03%	386
2025 Q2	$247K	Buy	+11,474	New	+$213K	0.03%	353
2021 Q1	–	Sell	-3,639	Closed	-$195K	–	354
2020 Q4	$195K	Buy	+3,639	New	+$181K	0.05%	287

Other funds holding ACAD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pinnacle Wealth Planning Services's ACAD Position: Q3 2026 in Review

Pinnacle Wealth Planning Services reduced its Acadia Pharmaceuticals (ACAD) stake by 28% in Q3 2026, selling an estimated $79.8K and leaving 7,530 shares worth $152K. The position accounts for 0.01% of the portfolio, ranked #626.

Pinnacle Wealth Planning Services first reported a position in ACAD in Q4 2020 and has held it in 7 quarters since. The position peaked at $299K in Q4 2025. 138 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

Pinnacle Wealth Planning Services held 7,530 shares of Acadia Pharmaceuticals worth $152K as of Q3 2026.
Pinnacle Wealth Planning Services sold 2,973 Acadia Pharmaceuticals shares in Q3 2026, an estimated $79.8K.
Acadia Pharmaceuticals made up 0.01% of Pinnacle Wealth Planning Services's portfolio in Q3 2026, its #626 holding.
Pinnacle Wealth Planning Services first reported a position in Acadia Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
Pinnacle Wealth Planning Services's Acadia Pharmaceuticals position peaked at $299K in Q4 2025.
138 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q3 2026, filed 27 Oct 2026.